Khiron achieves United Kingdom Cannabis Sales Volume Growth of 240% in Q1 2022 & More News Here

• In Q1 2022, Khiron expects to surpass 1 million CAD in medical hashish revenues in the United Kingdom (“UK”) alone

• Total untapped potential for hashish sufferers in the UK exceeds 1M sufferers

• Supported by its clinic in the UK opened in late 2021, Khiron has elevated its gross sales volumes greater than 240% in Q1 2022 in comparison with complete 2021

• Khiron’s rising portfolio in the UK contains KHIRON 20/1, one of the best-selling THC-predominant hashish flower in the UK market

TORONTO, May 10, 2022 /PRNewswire/ – Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), the worldwide medical hashish chief increasing all through Europe and Latin America, continues to show its market dominance in the UK’s medical hashish trade with hashish gross sales quantity development of 240% in Q1 2022 in comparison with all the 2021 yr. This development is generated by Khiron’s end-to-end resolution of authorities regulation, provide chain, distribution, and clinics prescribing Khiron’s medical hashish merchandise.

With a inhabitants of nearly 67 million, the UK has a possible of at the very least 1.5% medical hashish sufferers¹. Khiron addresses the good potential in the UK with its medical hashish merchandise and scientific companies, that are more and more utilized by sufferers and medical practitioners. In late 2021, Khiron opened its first European Zerenia™ Medical Cannabis Clinics in the UK, providing telemedicine service to sufferers across the nation, and contributing to the Company’s affected person acquisition and retention development.

“Today, Khiron has already established market leadership in the UK with it first two products on the market, and its KHIRON 20/1 THC-predominant strain is one of the best-selling medically prescribed products in the UK market,” feedback Franziska Katterbach, President of Khiron Europe. “In Q1 2022, we expect to surpass our first 1 million CAD in revenues in the UK, and as we expand our portfolio, and increase our patient base, Khiron will consolidate its market leadership within the country. In 2021, Europe accounted for 33% of Khiron’s medical cannabis revenues, at more than 1.5 million CAD. In Q1 2022 and beyond, Europe will represent over 50% of Khiron’s cannabis revenues, strengthening Khiron’s position as a leader in the global medical cannabis market.”

Story continues

Khiron is headquartered in Toronto, with operations in Colombia, Germany, UK, Peru, and Brazil

About Khiron Life Sciences Corp.
Khiron is a number one international medical hashish firm with core operations in Latin America and Europe. Leveraging wholly-owned medical well being clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented strategy, doctor education schemes, scientific experience, product innovation, and deal with creating entry to drive prescriptions and model loyalty with sufferers worldwide. The Company has a gross sales presence in Colombia, Germany, UK, Peru, and Brazil and is positioned to begin gross sales in Mexico. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, along with an skilled and numerous government group and Board of Directors.

Visit Khiron on-line at traders.khiron.ca

Linkedin https://www.linkedin.com/company/khiron-life-sciences-corp/

Cautionary Notes

Forward-Looking Statements

This press launch could include sure “forward-looking information” and “forward-looking statements” inside the that means of relevant securities laws. All data contained herein that’s not historic in nature could represent forward-looking data. Khiron undertakes no obligation to touch upon analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or monetary or working outcomes (as relevant). Although Khiron believes that the expectations mirrored in forward-looking statements in this press launch are cheap, such forward-looking assertion has been based mostly on expectations, elements and assumptions regarding future occasions which can show to be inaccurate and are topic to quite a few dangers and uncertainties, sure of that are past Khiron’s management, together with the danger elements mentioned in Khiron’s Annual Information Form which is out there on Khiron’s SEDAR profile at www.sedar.com. The forward-looking data contained in this press launch is expressly certified by this cautionary assertion and is made as of the date hereof. Khiron disclaims any intention and has no obligation or duty, besides as required by legislation, to replace or revise any forward-looking data, whether or not because of this of new data, future occasions or in any other case.

Neither the TSXV nor its Regulation Services Provider (as that time period is outlined in the insurance policies of the TSXV) accepts duty for the adequacy or accuracy of this press launch.

View unique content material to obtain multimedia:https://www.prnewswire.com/news-releases/khiron-achieves-united-kingdom-cannabis-sales-volume-growth-of-240-in-q1-2022-301543201.html

SOURCE Khiron Life Sciences Corp.

I’ve tried to present all types of information to all of you latest news today 2022 via this web site and you’re going to like all this information very a lot as a result of all of the information we all the time give in this information is all the time there. It is on trending matter and regardless of the newest information was

it was all the time our effort to achieve you that you simply preserve getting the newest information and also you all the time preserve getting the knowledge of information via us totally free and in addition let you know folks. Give that no matter data associated to different sorts of information shall be

made out there to all of you so that you’re all the time related with the information, keep forward in the matter and preserve getting today news all sorts of information totally free until in the present day so as to get the information by getting it. Always take two steps ahead